Form D · Pharmaceuticals
Indalo Therapeutics, Inc.
St. Louis, MO · CIK 0001654706
Offering snapshot reported Aug 1, 2017 · SEC filing
- Reported sold
- $9M Offering amount: $26M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 30, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 1, 2017 | Initial | $8,999,996 | No comparison | 6 | SEC filing |
| Oct 2, 2015 | Initial | $595,618 | No comparison | 5 | SEC filing |
| Oct 2, 2015 | Initial | $100,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-291882
Source: Form D, filed Aug 1, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ben Auspitz | Director |
| Peter Barrett | Director |
| Charles Bolten | Director |
| George H. Capps Ii | Executive, Promoter |
| George H. Capps, Ii | Executive |
| Thomas P. Cirrito | Director |
| Rajesh Devraj | Director |
| David W. Griggs | Director |
| Robert W. Karr | Director, Executive |
| Scott Seiwert | Executive |
| Bradford Williamson | Executive |
| Michael A. Yeadon | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4320 Forest Park Avenue Suite 304
St. Louis, MO, 63108
St. Louis, MO, 63108